Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,655 across all filing types
Latest filing 2023-12-28 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
第六届监事会第一次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of a resolution from the Supervisory Board meeting of Shenzhen Xintai Pharmaceutical Co., Ltd. It details the election of a new chairman of the Supervisory Board and confirms the legality and attendance of the meeting. There is no financial data, no mention of annual or interim reports, no audit information, and no regulatory certifications. The document is a formal announcement of board/management information, specifically about changes in the supervisory board leadership. Therefore, it fits best under the category of Board/Management Information (MANG). The document length is short and it is not a report publication or certification, so it is not RPA or RNS. Confidence is high due to clear content and context.
2023-12-28 Chinese
2023年第一次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a resolution announcement for the "2023 First Extraordinary General Meeting" of Shenzhen Salubris Pharmaceuticals Co., Ltd. It details the convening of the meeting, attendance, voting results on various proposals including election of board members and supervisors, amendments to company rules, and legal opinions on the meeting's validity. The content is focused on the official results of shareholder votes at a general meeting, including detailed vote counts and resolutions passed. There is no indication that this is a full annual report, audit report, or other financial report. The document is not a presentation or transcript but an official announcement of voting results from a shareholder meeting. Therefore, the appropriate classification is Declaration of Voting Results & Voting Rights Announcements (DVA). The document length (7054 characters) supports it being a full announcement rather than a brief notice or report publication announcement.
2023-12-28 Chinese
第六届董事会第一次会议决议公告
Board/Management Information Classification · 100% confidence The document is a detailed announcement of the resolutions passed at the first meeting of the sixth board of directors of Shenzhen Salubris Pharmaceuticals Co., Ltd. It includes election of the board chairman, appointment and reappointment of senior management personnel, composition of board committees, and detailed biographies of the appointed executives. The content focuses on board and senior management changes and appointments, with no financial statements or financial performance data. The document is not a report of financial results, audit, or regulatory filing but rather a formal announcement of board and management information. Therefore, the appropriate classification is 'Board/Management Information' (MANG). The document length (7595 characters) supports it being a full announcement rather than a brief notice or report publication announcement.
2023-12-28 Chinese
独立董事专门会议审核意见
Board/Management Information Classification · 95% confidence The document is a formal opinion from independent directors regarding the reappointment of senior management positions, including the general manager and other executives. It references compliance with company law, stock exchange listing rules, and internal company regulations. The content focuses on board/management personnel matters rather than financial results, audit opinions, or shareholder voting outcomes. The document length is short (952 characters) and it is not an announcement of a report publication but a direct statement of management appointments. Therefore, it fits best under Board/Management Information (MANG).
2023-12-28 Chinese
北京市金杜（广州）律师事务所关于深圳信立泰药业股份有限公司2023年第一次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the convening, procedures, attendance, and voting results of the 2023 first extraordinary general meeting (临时股东大会) of Shenzhen Salubris Pharmaceuticals Co., Ltd. It details the legal compliance of the meeting, the qualifications of attendees, the voting procedures, and the results of various board and supervisory board elections and other shareholder resolutions. The document is not a financial report, earnings release, or management discussion, but rather a legal opinion on the shareholder meeting and its outcomes. This type of document is typically classified as Declaration of Voting Results & Voting Rights Announcements (DVA) because it officially reports the voting results of a shareholder meeting and confirms the legality and validity of the meeting and its resolutions.
2023-12-28 Chinese
第三期员工持股计划（草案）摘要
Capital/Financing Update Classification · 95% confidence The document is a detailed draft summary of the third employee stock ownership plan (员工持股计划) of Shenzhen Salubris Pharmaceuticals Co., Ltd. It includes legal references, principles, participant details, funding sources, stock sources, lock-up periods, performance assessments, management structure, and procedural steps for implementation. The document is comprehensive and focuses on the employee stock ownership plan, which is a form of capital/financing update related to employee equity incentives. It is not an annual report, earnings release, or regulatory filing. It is not a proxy statement or voting result announcement. It is not a board or management change announcement. The document is not a report publication announcement but the actual plan draft. Therefore, the best fitting category is Capital/Financing Update (CAP). The document length (15,000 characters) and content confirm it is a full plan document, not just an announcement or summary. Confidence is high due to the detailed nature and focus on employee stock ownership plan specifics, funding, stock sources, and management.
2023-12-22 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.